Evaluating whether Rezolute, Inc. (NASDAQ: RZLT) is a sound purchase requires analyzing your risk tolerance for clinical-stage biotechnology equities. Rezolute focuses on developing novel therapies for rare metabolic and endocrine disorders, meaning its long-term financial viability and equity valuation depend almost entirely on successful clinical trial readouts, regulatory approvals from health agencies like the FDA, and subsequent commercialization milestones. While promising clinical pipeline assets offer substantial capital appreciation potential, biotech stocks carry extreme downside risk if drug candidates fail during trials or encounter regulatory delays. Consulting a licensed financial advisor is recommended before investing.